SFG
KRYS icon

Strive Financial Group’s Krystal Biotech KRYS Stock Holding History

Strive Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$372 Buy
+1
New +$299 ﹤0.01% 765

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Strive Financial Group's KRYS Position: Q2 2026 in Review

Strive Financial Group opened a new position in Krystal Biotech (KRYS) in Q2 2026: 1 share worth $372. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

421 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Strive Financial Group held 1 share of Krystal Biotech worth $372 as of Q2 2026.
  • Krystal Biotech was a new Strive Financial Group position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Strive Financial Group's portfolio in Q2 2026, its #765 holding.
  • 421 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Strive Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.